China's largest AI-enabled healthcare platform — connecting 240 million patients to 320,000 doctors across 11,500 hospitals, and finally heading for a long-awaited public listing.
China has 1.4 billion people and a healthcare system built for a fraction of them. Every day, hundreds of patients queue for hours outside major hospitals in Beijing and Shanghai — not because there are no doctors in China, but because all the best doctors are concentrated in a handful of top-tier urban hospitals. A patient in rural Sichuan with a chronic condition faces a choice between inadequate local care and a 12-hour journey to a major city clinic.
This is the problem Jerry Liao set out to solve in 2010 when he founded what was then called Guahao.com — a simple platform to book hospital appointments online. The insight was straightforward: the bottleneck in Chinese healthcare is not the number of doctors, but access to them. Technology could dissolve that bottleneck entirely.
WeDoctor has since evolved far beyond appointment booking into a full-stack healthcare ecosystem. A patient can consult a specialist via video call, receive an AI-assisted diagnosis, get an electronic prescription fulfilled at a linked pharmacy, manage chronic conditions through a membership programme, and access health insurance — all without leaving their phone. For the 600 million Chinese in lower-tier cities and rural areas, this is not a convenience upgrade. It is their primary access point to quality medical care.
Why now: Three forces are converging. China's ageing population is creating a surge in chronic disease management demand. The government's Healthy China 2030 policy explicitly mandates digital health expansion as national infrastructure. And AI has matured to the point where diagnostic assistance, personalised treatment recommendations, and predictive health management can be delivered at scale through a mobile platform.
China's healthcare market is one of the largest and fastest-growing in the world. Total healthcare spending is projected to reach 16 trillion yuan by 2030. The digital health sub-segment — which includes telemedicine, internet hospitals, and AI-assisted diagnosis — is growing at a compound annual rate of 11% and is expected to reach $19 billion by 2034. The AI-enabled healthcare solutions market specifically, where WeDoctor holds the number one position by revenue, is projected to grow at 46% CAGR to reach 138 billion yuan by 2030.
What makes this market structurally different from other digital health markets is the degree of government support. China's Healthy China 2030 blueprint treats internet healthcare as national infrastructure, not merely a commercial sector. WeDoctor has benefited from this policy alignment — it built China's first internet hospital in Wuzhen in 2015, a milestone that was only possible with regulatory approval that has since opened the door for the entire industry.
The ageing population tailwind is also unusually strong. By 2035, more than 400 million Chinese will be over 60. Chronic disease management — diabetes, hypertension, cardiovascular disease — is where WeDoctor's membership model is positioned to generate the most durable recurring revenue. These are patients who need regular monitoring, medication management, and specialist consultations: the exact service stack WeDoctor has spent 15 years building.
WeDoctor operates across four integrated business segments, each generating revenue from a different part of the healthcare value chain. The key shift in recent years is the move toward health management membership services — a subscription model that generates predictable recurring revenue rather than transactional consultation fees.
| Segment | Model | Revenue Driver |
|---|---|---|
| WeDoctor Healthcare | Consultation fees + membership | Online consultations, AI diagnosis, chronic disease management subscriptions |
| WeDoctor Cloud | SaaS licensing to hospitals/govt | AI diagnostic tools, hospital management systems, government health platforms |
| WeDoctor Insurance | Premium commission | Health and life insurance products distributed through the platform |
| WeDoctor Pharma | Transaction fee / margin | Electronic prescription fulfilment through linked pharmacies |
The membership shift is the most important story: WeDoctor's H1 2024 revenue more than doubled to 1.82 billion yuan, driven explicitly by "the continued expansion of health management membership services." This signals a business model that is maturing from a transactional appointment-booking utility into a recurring-revenue health management platform — a far more defensible and valuable business.
The cloud segment is strategically important and often underappreciated. WeDoctor Cloud sells AI diagnostic tools and hospital management software directly to public hospitals and government health authorities. This creates government relationships and data pipelines that are nearly impossible for a new entrant to replicate. It also means WeDoctor's revenue is partially anchored by public sector contracts rather than purely consumer discretionary spending.
WeDoctor's scale is genuinely difficult to comprehend from the outside. By June 2025, the platform was connected to approximately 11,500 medical institutions and 320,000 doctors across China. The registered user base stands at 240 million. For context, that is more registered users than the entire population of Brazil.
Key milestones that define the moat: WeDoctor built China's first internet hospital in Wuzhen in 2015 — a genuine industry-defining event that shaped the entire regulatory framework for internet healthcare in China. In 2023, it became the number one company in China's AI-enabled healthcare solutions market by revenue. In 2025, it filed its IPO application to the Hong Kong Stock Exchange, targeting $400 to $500 million in proceeds.
The revenue doubling in H1 2024 is the most compelling recent data point. It suggests the membership model is reaching genuine product-market fit — customers are not just using WeDoctor once for an appointment but enrolling in ongoing health management programmes. This is the recurring revenue transition that transforms a utility into a platform.
Jerry Liao Jieyuan (Founder and CEO) is an AI expert and serial entrepreneur who previously co-founded ChinaHR.com, one of China's largest online recruitment platforms, and was an early co-founder of iFlytek, the world-leading voice recognition company. His background sits at the intersection of AI technology and large-scale consumer platforms — exactly the combination needed to build what WeDoctor has become. He founded WeDoctor in 2010 after experiencing first-hand the failures of China's healthcare access system while trying to get care for family members.
The founding motivation matters here. WeDoctor was not built by a management consultant identifying a market gap. It was built by someone who encountered the problem personally and had both the technical capability and the network to do something about it at scale. That founder-market fit has driven 15 years of consistent expansion into adjacent healthcare verticals.
The executive team includes experienced operators from China's tech and healthcare sectors. The CFO appointment of John Cai, formerly CEO of AIA Group's Asian operations, is a notable signal — bringing insurance industry expertise and investor relations credibility ahead of the IPO process.
WeDoctor competes in China's internet healthcare market alongside three major players, each with a different strategic anchor. The competitive dynamic is less about head-to-head product rivalry and more about which ecosystem each company is embedded in — Tencent (WeDoctor), Alibaba (AliHealth), JD.com (JD Health), and Ping An Group (Good Doctor).
WeDoctor's key differentiator is vertical integration. Ping An Good Doctor does telemedicine well. AliHealth does pharmacy well. JD Health does supply chain well. WeDoctor is the only platform that connects all four legs of the healthcare value chain in a single ecosystem — and the only one that has built meaningful B2B cloud infrastructure sold directly to hospitals and government. That cloud segment is the least replicable part of the business and the most strategically important for long-term defensibility.
China's digital health ecosystem is one of the most government-supported innovation sectors in the country. The Healthy China 2030 plan treats internet healthcare as national infrastructure, setting explicit targets for digital health coverage that create structural demand regardless of consumer sentiment cycles. This is a rare environment where a startup's growth trajectory is partially underwritten by state policy.
Funding ecosystem: China's healthcare sector attracted over $20 billion in digital health venture capital across more than 1,300 deals since the ecosystem began. The leading investors — Tencent, Hillhouse, HongShan (formerly Sequoia China), AIA — represent a combination of strategic and financial capital that is particularly well-suited to healthcare, where both patient capital and operational expertise are required.
Exit landscape: The HKEX has established itself as the primary listing venue for Chinese healthcare companies, with AliHealth, JD Health, and Ping An Good Doctor all trading there. The comparable public companies provide a clear valuation framework — and all three have demonstrated that China's internet healthcare model can sustain public market interest over time.
Government tailwinds: WeDoctor built China's first internet hospital with government approval, participated in China's national COVID-19 response with free online consultation services, and has cloud contracts with multiple provincial health authorities. The government-to-business relationship creates both revenue stability and regulatory protection that pure consumer platforms do not have.
Talent and infrastructure: Hangzhou, where WeDoctor is headquartered, is China's second most significant tech hub after Beijing-Shanghai, anchored by Alibaba and a deep ecosystem of healthcare and AI engineering talent. The concentration of both tech and biomedical expertise in the Yangtze River Delta creates a structural advantage for recruitment.
| Round | Year | Lead / Key Investors | Amount | Valuation |
|---|---|---|---|---|
| Series A-C | 2012-2015 | Tencent, Goldman Sachs, Hillhouse | ~$400M | ~$1B est. |
| Pre-IPO | 2018 | AIA Group, NWS Holdings | $500M | $5.5B |
| Growth Round | 2020 | Sequoia China, Millennium Management | $400M | $6.8B |
| Series G | 2022 | Shandong Guotou | $163M | $7B |
| IPO Filing | 2025 | HKEX · China Merchants Bank (sponsor) | $400-500M target | TBD |
Investor signal value: The combination of Tencent (strategic ecosystem), AIA (insurance distribution partner), Hillhouse (long-term Asia healthcare specialist), and HongShan (deep China tech expertise) is among the strongest possible investor lineups for a China healthtech company. Each investor brings strategic value beyond capital: Tencent provides WeChat distribution, AIA provides insurance product partnership, Hillhouse provides healthcare sector depth.
IPO use of proceeds: WeDoctor has stated it will use IPO capital to expand its partnership model across China, elevate AI technologies and applications, improve service quality and management efficiency, and fund working capital. The AI investment is particularly strategic — the AI-enabled healthcare solutions market where WeDoctor holds the number one position is projected to grow at 46% CAGR to 2030.
Valuation context: The $7B valuation from 2022 was set in a more challenging market environment. With H1 2024 revenue doubling and a recovering HKEX market, the IPO valuation will be set against comparable public companies — Ping An Good Doctor (currently trading at approximately $1-2B market cap after significant decline from peak), JD Health (~$6B), and AliHealth (~$3B). WeDoctor's IPO valuation will likely need to be set conservatively to clear given the competitive listed comparables.
This memo is for informational purposes only. Not financial advice. Memobird Research does not hold positions in the securities discussed. All data sourced from public filings, company press releases, analyst reports, and primary research as of April 2026. Revenue figures are from WeDoctor's HKEX IPO filing documents and have not been independently verified.